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Background: Ginsenoside Rh2 (GRh2) is the main bioactive component in American ginseng, a
commonly used herb, and its antitumor activity had been studied in previous studies. PDZ-binding ki-
nase/T-LAK cell-originated protein kinase (PBK/TOPK), a serine/threonine protein kinase, is highly
expressed in HCT116 colorectal cancer cells.
Methods: We examined the effect of GRh2 on HCT116 cells ex vivo. Next, we performed in vitro binding
assay and in vitro kinase assay to search for the target of GRh2. Furthermore, we elucidated the un-
derlying molecular mechanisms for the antitumor effect of GRh2 ex vivo and in vivo.
Results: The results of our in vitro studies indicated that GRh2 can directly bind with PBK/TOPK and GRh2
also can directly inhibit PBK/TOPK activity. Ex vivo studies showed that GRh2 signiﬁcantly induced cell
death in HCT116 colorectal cancer cells. Further mechanistic study demonstrated that these compounds
inhibited the phosphorylation levels of the extracellular regulated protein kinases 1/2 (ERK1/2) and (H3)
in HCT116 colorectal cancer cells. In vivo studies showed GRh2 inhibited the growth of xenograft tumors
of HCT116 cells and inhibited the phosphorylation levels of the extracellular regulated protein kinases 1/
2 and histone H3.
Conclusion: The results indicate that GRh2 exerts promising antitumor effect that is speciﬁc to human
HCT116 colorectal cancer cells through inhibiting the activity of PBK/TOPK.
Copyright 2016, The Korean Society of Ginseng, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
PDZ-binding kinase/T-LAK cell-originated protein kinase (PBK/
TOPK), a serineethreonine mitogen-activated protein kinase, is a
member of theMEK protein family [1,2]. It is involved in themitotic
checkpoint of cells [3], DNA damage [4], tumor transformation andmicrobiology, Medical College of Y
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d/4.0/).metastasis [5,6], and inﬂammation [7]. Previous studies showed
that PBK/TOPK is highly expressed in many cancers such as lym-
phoma, leukemia, melanoma, breast cancer, lung cancer, chol-
angiocarcinoma, glioma, and colorectal cancer [8e14]. It may play
an important role in prognostic and predictive diagnosis and ther-
apy in cancer. In addition, it was reported that PBK/TOPK is highlyan’an University, No 38 Guanghua Road, Baota District, Yan’an City, Shanxi Province
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J. Yang et al / GRh2 inhibits HCT116 cells 401expressed in HCT116 colorectal cancer cells [14,15], and the positive
feedback loop between PBK/TOPK and extracellular regulated pro-
tein kinase (ERK) 2 increases tumorigenesis of HCT116 colorectal
cancer cells [14]. Also, studies have shown that PBK/TOPK could
phosphorylate histoneH3 (H3) at Ser10 in vitro and in vivo [12]. PBK/
TOPK may be a valid target for antineoplastic kinase inhibitors to
sensitize tumor cells to chemotherapy-induced apoptosis and
growth suppression [15]. However, there are few PBK/TOPK in-
hibitors reported in basic research. One PBK/TOPK inhibitor HI-
TOPK-032 [16], OTS964 [17], has great suppression in colon cancer
andother cancers, but has signiﬁcant side-effects [17]. Therefore,we
aimed to look for a traditionalmedicine to inhibit PBK/TOPK activity.
Ginsenosides are the main active chemical constituents of
ginseng, the root of Panax ginseng Meyer [18], which has great
pharmacological efﬁcacy to promote the human health in global
traditional medicine, such as antidiabetic, anti-inﬂammatory,
antitumor, anti-UV radial, protection of nerves, regulation of
blood pressure, and other functions [19e22]. Ginsenosides could be
classiﬁed in three types based on aglycone moieties:
protopanaxadiol-type ginsenosides, protopanaxatriol-type ginse-
nosides, and oleanolic acid-type ginsenosides [22]. Ginsenoside
Rh2 (GRh2), identiﬁed as an protopanaxadiol-type ginsenoside,
exhibits signiﬁcant antitumor effects on pancreatic cancer, leuke-
mia, prostatic cancer, skin squamous cell carcinoma, glioblastoma,
and so on [23e27]. Some protopanaxadiol-type ginsenosides, such
as ginsenosides Rb1/2 and Rg3, are metabolized to GRh2 by human
intestinal bacteria [28]. GRh2 exists in two stereoisomeric forms,
20(R)-GRh2 and 20(S)-GRh2 (Fig. 1A). Compared to 20(R)-GRh2,
20(S)-GRh2 displays an evident anticancer activity through sup-
pressing cell proliferation in human lung adenocarcinoma A549
cells [29], and inhibiting proliferation of androgen-dependent or
independent prostate cancer cells [30].
Signiﬁcant antitumor effects of ginsenosides are observed in
colorectal cancer cells [31,32]. However, its detailed mechanismFig. 1. Chemical structure of GRh2 and its effect on EGF-induced neoplastic transformatio
inhibits EGF-induced anchorage-independent growth of HCT116 cells in a dose dependent
periments. * Signiﬁcant compared with control alone, p < 0.05. ** Signiﬁcant compared with
used after different concentration of GRh2 treatment for 24 h.remains unclear. Thepresent study is theﬁrst to investigatewhether
GRh2 effectively targets PBK/TOPK by directly binding to PBK/TOPK,
resulting in the inhibition of HCT116 cells in vivo and in vitro.
2. Materials and methods
2.1. Reagents and antibodies
HCT116 colorectal cancer cell lines were purchased from ATCC
(Manassas, VA, USA). Commercial GRh2was obtained fromWeikeqi
Bioscience (Chengdu, China). The GRh2 was prepared in a stock of
100 mg/mL and applied to cultured HCT116 cells at 5mM, 15mM,




active ERK2, inactive ERK2, H3 protein for kinase assays were
purchased from Millipore (Billerica, MA, USA). Antibodies to detect
total PBK/TOPK, phospho-PBK/TOPK (p-PBK/TOPK; T9), total ERK1/
2, phospho-ERK1/2 (p-ERK1/2; T202/Y204), total H3 and phospho-
H3 (p-H3; S10) were purchased from Cell Signaling Technology
(Danvers, MA, USA). Antibodies to detect b-actin were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
2.2. Cell culture and MTS assay
HCT116 colorectal cancer cell lines were cultured at 37C in a 5%
CO2 incubator in McCoy’ s 5A medium containing 10% fetal bovine
serum (FBS). The cells were starved for 24 h before the addition of
20 ng/mL epidermal growth factor (EGF) in McCoy’s 5A medium
without serum.
To estimate cytotoxicity, cells were seeded (8  103 cells per
well) in 96-well plates and cultured overnight. Cells were then fed
with fresh medium and treated with different concentrations ofn and signal transduction in HCT116 cells. (A) Chemical structure of GRh2. (B) GRh2
manner. (C) Histogram shown as means  SD of values from three independent ex-
EGF alone, p < 0.05. (D) Cytotoxic effects of GRh2 on HCT116 cells. An MTS assay was
Fig. 2. GRh2 inhibits TOPK activity by directly binding with TOPK. (A, B) GRh2 inhibits TOPK activity in vitro kinase assays in a dose dependent manner. Inactive (A) ERK2 and (B)
histone H3 were used as the substrate for in vitro kinase assays with active TOPK and 100mM ATP. Proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis and detected by Western blot using speciﬁc phosphor-antibody. The asterisk indicates a signiﬁcant difference between groups treated with different concentration of
GRh2 and the DMSO alone (* p < 0.05). (C) GRh2 has no effects on the ERK2 activity. (D) Sepharose 4B was used for binding and pull-down assays as described in the Materials and
methods section.
J Ginseng Res 2016;40:400e408402GRh2. After culturing for various times, the cytotoxicity of GRh2
was measured using an MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2H-tetrazdium] assay kit (Promega,
Madison, WI, USA) according to the manufacturer’s instructions.
2.3. Western blot
HCT116 colorectal cancer cells (1.5  106) were cultured for 48 h
and starved in serum-free medium for 24 h without FBS. The cells
were treated with GRh2 (5mM, 15mM, 25mM, 50mM) for 3 h, 6 h, and
12hbefore exposure to 20ng/mLEGF.Harvested cellsweredisrupted
and protein concentrations were determined by the Bradford
method. Lysate proteinwas subjected to 10% sodiumdodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto
polyvinylidene ﬂuoride membranes, which were incubated with a
speciﬁc primary antibody at 4C for overnight. Proteins werevisualized using a chemiluminescence detection kit after hybridiza-
tion with a horseradish peroxidase-conjugated secondary antibody.
2.4. Anchorage-independent transformation assay
The cells (8  103/mL) were exposed to EGF (20 ng/mL) and
treated with GRh2 (0e50mM) in 1 mL of 0.3% Basal Medium Eagle
agar containing 10% FBS, 2mM L-glutamine, and 25 mg/mL genta-
micin. The culturesweremaintainedat37C, ina5%CO2 incubator for
7e14 d, and the colonies were counted under a microscopewith the
aid of Image-Pro Plus v.4 (Media Cybernetics, Silver Spring,MD,USA).
2.5. Immunohistochemistry
For p-ERK and p-H3 immunostaining, antigen retrieval was per-
formed by microwave after deparafﬁnization and rehydration of
J. Yang et al / GRh2 inhibits HCT116 cells 403tissue sections (5mm) for 10min in sodiumcitrate buffer. The sections
were cooled to room temperature, treatedwith 3%H2O2 inmethanol
for 10 min and blocked with 6% horse serum for 40 min at room
temperature. The sections were incubated at 4C overnight with
primaryantibodies. The sectionswerewashed inphosphate-buffered
saline and incubated with the secondary antibody for 30 min. After
washing, colorwasdevelopedby the indirect avidin/biotin-enhanced
horseradish peroxidase method with the horseradish peroxidase kit
and with 3,3-diaminobenzidine tetrahydrochloride as substrate. For
evaluation, photomicrographs were takenwith a digital camera. The
positively stained cells within each photomicrograph were counted.2.6. In vitro kinase assay
Inactive ERK2 and H3 proteins were used as the substrate for an
in vitro kinase assay with active PBK/TOPK. Firstly, active PBK/TOPK
was incubated with GRh2 (10mM, 20mM, and 50mM) in 1kinase
buffer (25mM Tris-HCl pH 7.5, 5mM b-glycerophosphate, 2mM
dithiothreitol, 0.1mM Na3VO4, 10mM MgCl2) at 30C for 10 min.
Then, inactive substrate and 100mM ATP were added to reactionFig. 3. TOPK is required for GRh2-inhibition of the phosphorylation of ERK1/2 and p90RSK in
TOPK/ERK signaling pathway in a dose-dependent manner. HCT116 cells starved in serum-fre
stimulation with EGF (20 ng/mL) for 15 min, cell were harvested and protein levels were de
time-dependent manner. HCT116 cells were starved in serum-free medium for 24 h, and tre
for 15 min, cells were harvested and protein levels were determined by western blot ana
quantiﬁed by scanning densitometry and normalized to ERK1/2 or b-actin protein. The va
experiments. * Signiﬁcant compared with control alone, p < 0.05.** Signiﬁcant compared wand incubated at 32C for 1 h. Reactions were stopped and proteins
detected by Western blotting.
2.7. In vitro binding assay
HCT116 cell lysates (1 mg) were incubated with the GRh2, or
GRh2-Sepharose 4B beads in the reaction buffer [50mM Tris (pH
7.5), 5mM ethylenediaminetetraacetic acid, 150mM NaCl, 1mM
dithiothreitol, 0.01% Nonidet P-40, 2 mg/mL bovine serum albumin,
0.02mM phenylmethylsulfonyl ﬂuoride, and 1 mg/mL protease in-
hibitor mixture]. After gentle rocking overnight at 4C, the beads
werewashedﬁve times andproteinswere analyzedbyWestern blot.
2.8. Xenograft mouse model
Athymic nude mice (NIH Swiss nude, age 6e9 wk) were ob-
tained from the animal center of the Fourth Military Medical Uni-
versity (No. 169, Changle West Road, Xi’an, Shaanxi, 710032, PR
China). Mice were divided into different groups (n ¼ 10 of each
group). HCT116 colorectal cancer cells (4  106/0.1 mL) were
injected subcutaneously into the right ﬂank of eachmouse. GRh2 orduced by EGF in HCT116 cells in a dose- and time-dependent manner. (A) GRh2 inhibits
e medium for 24 h, and treated with GRh2 at the indicated concentration for 12 h. After
termined by western blot analysis. (B) GRh2 inhibits TOPK/ERK signaling pathway in a
ated with GRh2 at the indicated time for 20mM. After stimulation with EGF (20 ng/mL)
lysis using speciﬁc antibodies. The phosphorylation level of ERK1/2 and p90RSK was
lues shown are mean  standard error of the mean of data from three independent
ith EGF alone, p < 0.05.
J Ginseng Res 2016;40:400e408404vehicle was injected three times a week for 29 d. Tumor volumes
and body weights were measured. Tumor tissues from mice were
embedded in a parafﬁn block and subjected to immunohisto-
chemistry or hematoxylin and eosin staining.2.9. Statistical analysis
All quantitative data are expressed as mean values  standard
deviation, and signiﬁcant differences were determined by Student t
test or by one-way analysis of variance in SPSS version 13.0 soft-
ware (SPSS Inc., Chicago, IL, USA). A probability value of p < 0.05
was used as the criterion for statistical signiﬁcance.3. Results
3.1. GRh2 suppresses HCT116 cells induced by EGF to anchor the
dependency proliferation
In the present study, we ﬁrst examined the effect of GRh2 on
EGF-induced neoplastic transformation of HCT116 cells. Treatment
of HCT116 cells with GRh2 signiﬁcantly reduced EGF-induced
neoplastic transformation in soft agar in a dose-dependent
manner (Fig. 1B). GRh2 at 25mM or 50mM caused a reduction to
62% or 85% of control, respectively, and the difference was statis-
tically signiﬁcant (p < 0.05; Fig. 1C). We can see that the viability of
HCT116 cells was not affected by the 50mMGRh2, while many dead
HCT116 cells were seen when GRh2 concentration was 100mM
(Fig. 1D). The results show that GRh2 signiﬁcantly inhibits HCT116
cells growth in soft agar in a dose-dependent manner in the
effective concentration range of GRh2.Fig. 4. TOPK is required for GRh2 inhibition of the phosphorylation of histone H3 induced by
signaling pathway in a dose-dependent manner. HCT116 cells were starved in serum-free m
stimulation with EGF (20 ng/mL) for 15 min, cells were harvested using the extraction meth
inhibits TOPK/H3 signaling pathway in a time-dependent manner. HCT116 cells were starved
After stimulation with EGF (20 ng/mL) for 15 min, cell were harvested using the extraction
phosphorylation level H3 was quantiﬁed by scanning densitometry and normalized to total H
independent experiments. * Signiﬁcant compared with control alone, p < 0.05. ** Signiﬁca3.2. GRh2 is a potent inhibitor of PBK/TOPK activity and binds
directly with PBK/TOPK
To identify a potent inhibitor of PBK/TOPK, we examined more
than 12 compounds that have antitumor effect using the in vitro
kinase assay. We identiﬁed GRh2 as a good inhibitor of PBK/TOPK.
To determine the effects of GRh2 on PBK/TOPK activity we used
ERK2 as the substrate of PBK/TOPK. The phosphorylation of EKR2
was strongly inhibited by GRh2 in a dose-dependent manner. For
example, 20mMGR2h resulted in about 58% inhibition of PBK/TOPK
activity and 50mMcaused about 78% inhibition of PBK/TOPK activity
(Fig. 2A). We also used inactive H3 as a substrate for PBK/TOPK and
results indicated that the phosphorylation of H3 on Ser10 was also
dose dependently suppressed by GRh2 treatment. GRh2 at 20mM
resulted in about 63% inhibition of PBK/TOPK activity and 50mM
caused about 80%; the difference was statistically signiﬁcant
(p < 0.05; Fig. 2B). In addition, we investigated whether GRh2
inhibited the ERK2 activity; the result clearly shows that GRh2 does
not directly inhibit ERK2 activity (Fig. 2C). These results notably
support that GRh2 directly inhibits PBK/TOPK activity.
The in vitro kinase assay results show that GRh2 inhibits PBK/
TOPK activity, which implies direct binding between GRh2 and
PBK/TOPK. To conﬁrm this idea, we performed an in vitro binding
assay using GRh2-conjugated sepharose 4B beads or sepharose 4B
beads alone in HCT116 cells lysate that had been veriﬁed to express
PBK/TOPK highly. A strong band representing PBK/TOPK was
observed in the GRh2-conjugated beads group, whereas no obvious
bandwas seen in the beads alone group (Fig. 2D). The results clearly
indicate that GRh2 could directly bind with PBK/TOPK protein.
Therefore, these above results show that GRh2 could directly bind
to PBK/TOPK and inhibit PBK/TOPK activity.EGF in HCT116 cells in a time- and dose-dependent manner. (A) GRh2 inhibits TOPK/H3
edium for 24 h, and treated with GRh2 at the indicated concentration for 12 h. After
od of histones, and protein levels were determined by western blot analysis. (B) GRh2
in serum-free medium for 24 h, and treated with GRh2 at the indicated time for 20mM.
method of histones, and protein levels were determined by western blot analysis. The
3 protein. The values shown are mean  standard error of the mean of data from three
nt compared with EGF alone, p < 0.05.
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dependent manner in HCT116 cells
Previous studies suggested that PBK/TOPK/ERK2 signaling
pathway is highly activated in human colorectal cancer [14].
Therefore, we examined p-PBK/TOPK, p-ERK1/2, and p-p90RSK,
which is the downstream signaling pathway of ERK1/2 in HCT116
cells. HI-TOPK-032, a well-known inhibitor of PBK/TOPK, was used
as a positive control in the experiment [16]. Western blot results
suggested that phosphorylation of PBK/TOPK has no signiﬁcant
change. However, the phosphorylation of ERK1/2 in HCT116 cells
was strongly suppressed by GRh2 in a dose- and time-dependent
manner at the condition of EGF (20 ng/mL) stimulation. For
example, 10mM GR2h caused about 43% inhibition of the phos-
phorylation of ERK1/2, and 20mMand 50mMGR2h resulted in about
67% and 81% inhibition, respectively, of the phosphorylation of
ERK1/2 after 12 h (Fig. 3). Phosphorylation of p90RSK was also
strongly suppressed by GRh2. For example, 20mM GR2h induced
about 85% inhibition of p90RSK phosphorylation, similar to HI-
TOPK-032 (Figs. 3A and 3B). These data indicate that GRh2 sup-
presses the phosphorylation of ERK1/2 through inhibiting the PBK/
TOPK activity in HCT116 cells.3.4. GRh2 inhibits phosphorylation of H3 in a time- and dose-
dependent manner in HCT116 cells
Previous studies conﬁrmed that cell cycle dependent phos-
phorylation of H3 at Ser10 was well correlated with PBK/TOPK
expression level, particularly in the early stage of mitosis. It wasFig. 5. Knockdown of TOPK in HCT116 cells decreases sensitivity to GRh2. (A) Efﬁciency of T
cells transfected with shMock or shTOPK. (C) The relative clone number from A was qua
mean  standard error of the mean of data from three independent experiments. * Signiﬁc
with shMock or shTOPK to treatment with GRh2.reported that PBK/TOPK/H3 signaling pathway may promote
mitotic events, thus enhancing cancer cell proliferation [33], and
endogenous PBK/TOPKphosphorylatedH3at the Ser10 site in breast
cancer cells [12].We also veriﬁed that PBK/TOPKphosphorylatedH3
in vitro; we further detected the change of phosphorylation of H3 in
HCT116 cells. HI-TOPK-032, also was used as a positive control.
Western blot results showed that the phosphorylation of H3 was
strongly inhibited by GRh2 in a dose- and time-dependent manner
at the condition of EGF (20 ng/mL) stimulation (Fig. 4). The PBK/
TOPK inhibitorHI-TOPK-032also suppressed thephosphorylationof
H3, similar to GRh2. These results show that GRh2 inhibits the
phosphorylation of H3 in a dose- and time-dependent manner
through inhibiting the PBK/TOPK activity in HCT116 cells.3.5. Knockdown of PBK/TOPK in HCT116 cells decreases the
sensitivity of GRh2
We then examined whether knockdown PBK/TOPK expression
inﬂuences the sensitivity of HCT116 cells to GRh2. First, we deter-
mined the efﬁciency of PBK/TOPK knockdown by Western blot and
anchorage-independent growth. The expression of PBK/TOPK was
obviously decreased after knocking down PBK/TOPK compared
with the control group (Fig. 5A). In soft agar the growth of HCT116
cells in the knockdown PBK/TOPK group also decreased > 60%
compared with the control group (Figs. 5B and 5C). HCT116 cells
transfected with the shPBK/TOPK or shMock group were treated
with GRh2 or control and subjected to soft agar assay. The results
show that 20mMGRh2 inhibits the clone of HCT116 cells transfected
with shMock by 60%. By contrast, inhibition by clone was onlyOPK small hairpin RNA in HCT116 cells. (B) Anchorage-independent growth of HCT116
ntiﬁed by scanning densitometry and normalized to shMock. The values shown are
ant compared with shMock group, p < 0.05. (D) Sensitivity of HCT116 cells transfected
J Ginseng Res 2016;40:400e408406about 29% in HCT116 cells transfected with shPBK/TOPK, making
clear that HCT116 cells transfected with shPBK/TOPK are more
resistant to GRh2 treatment (Fig. 5D). These results indicate that
PBK/TOPK plays an important role in the sensitivity of HCT116
colorectal cancer cells to the antiproliferative effects of GRh2.
3.6. GRh2 inhibits the growth of tumor in vivo
To explore the antitumor efﬁcacy of GRh2 in xenograft model,
we injected subcutaneously into the left ﬂank of 6-wk-old athymic
nudemice using HCT116 cells. Micewere then administered vehicle
or GRh2 by injection of 10 mg/kg or 50 mg/kg three times a week
for 26 d. The data indicate 10 mg/kg or 50 mg/kg of GRh2 signiﬁ-
cantly suppressed HCT116 tumor growth by 49% and 78% relative to
the vehicle groups (Fig. 6A). However, the weight of mice had no
signiﬁcant difference between the vehicle and GRh2-treated group
(Fig. 6B). The effect of GRh2 on PBK/TOPK protein targets was
evaluated by immunochemistry and hematoxylineeosin staining of
HCT116 tumor tissues. The expression of p-ERK1/2 and p-H3 was
markedly decreased after treatment with GRh2 at either 10 mg/kg
or 50mg/kg (Figs. 6C and 6D). These data further indicate that GRh2
could inhibit HCT116 tumor growth and PBK/TOPK activity in vivo.
4. Discussion
Previous reports showed that the serineethreonine kinase PBK/
TOPK contributes to oncogenic functions including cancerFig. 6. Efﬁciency of GRh2 on colon cancer growth and TOPK targets in a HCT116 xenogra
average volume of mice were plotted over 24 d after tumor cell injection. Data are shown as
compared with control, p < 0.05. (B) GRh2 has no effect on mouse body weight. Body we
immunohistochemistry analysis of tumor tissues. Tumor tissue slides were prepared with
eosin, p-ERK antibody, and p-H3 antibody. (D) Quantiﬁcation of expression of p-ERK and p
shown as integrated optical density units.development, proliferation, metastasis, and antiapoptotic effects.
However, PBK/TOPK crystal structure has not been determined,
which may be the constraint to PBK/TOPK inhibitor development.
On the basis of preliminary anticarcinogen traditional medicine
reports, we selectedmore than 10 traditional compounds by in vitro
kinase assay and identiﬁed GRh2 as a potent PBK/TOPK inhibitor.
While American ginseng has been reported to have potential
chemopreventative effects relevant to colon cancer [34e37], the
concrete mechanism explaining its effective antitumor ingredient
GRh2 has not yet been elucidated in colorectal cancer. Previous
studies revealed that ginsenosides induce apoptosis and anti-
proliferative mechanism in HT-29 colon cancer cells, and are
involved in mitotic inhibition, DNA replication, and growth factor
signaling pathway [38,39]. Our study also showed that GRh2 can
promote HCT116 cells apoptosis in the optimal concentration of
GRh2. The anchorage-independent cell transformation assay
revealed that GRh2 effectively inhibits EGF-induced transformation
of HCT116 cells in a dose-dependent manner. In addition, another
report showed that HCT116 cells treated with American ginseng
were arrested in the G0/G1 phase of the cell cycle and the
expression of p53 and p21 proteins were increased, while p-MEK
was decreased [40]. PBK/TOPK, like constitutively activated MEK, is
overexpressed in many malignant cancer cells, especially HCT116
colorectal cancer cells [14,15]; there is a positive feedback loop
between PBK/TOPK and ERK2 that increases tumorigenesis prop-
erties of HCT116 colorectal cancer cells [14]. PBK/TOPK can also
phosphorylate H3 at Ser10 site to promote mitotic events, and thenft mouse model. (A) GRh2 signiﬁcantly suppresses colorectal cancer cell growth. The
mean  standard error of the mean from three independent experiments. * Signiﬁcant
ights of mice were measured once every 6 d. (C) Hematoxylin and eosin staining and
parafﬁn sections after ﬁxation with formalin and then stained with hematoxylin and
hospho-H3 in tumor tissues using the Image-Pro Plus software program and data are
J. Yang et al / GRh2 inhibits HCT116 cells 407enhancing cancer cell proliferation and transformation [12]. PBK/
TOPK reportedly plays an important role in the negative regulation
of P53 expression in HCT116 colorectal cancer cells [15]. GRh2
induced apoptosis and paraptosis-like cell death in colorectal
cancer HCT116 cells through activation of p53 [41]. Thus, the PBK/
TOPK signaling pathway is likely to play an important role in the
antitumor activity of GRh2.
We determined whether GRh2 could inhibit the PBK/TOPK ac-
tivity using ERK2 and H3 as a substrate of PBK/TOPK in an in vitro
kinase assay. The results showed that GRh2 inhibited the PBK/TOPK
activity in a dose dependent manner, while the ERK2 activity was
not inﬂuenced by GRh2. We further investigated whether GRh2
mediated the PBK/TOPK signaling pathway in HCT116 cells; the
results clearly showed that GRh2 could reduce the expression level
of p-ERK1/2 and p-H3 in a dose-dependent manner. In addition,
knocking down PBK/TOPK expression reduced the sensitivity of
HCT116 cells to GRh2 treatment. Furthermore, in vivo studies of
xenograft mouse model indicate that GRh2 inhibited PBK/TOPK
activity in tumor tissues resulting in inhibition of tumor growth.
In conclusion, the present study identiﬁed that PBK/TOPK is a
direct and important target of GRh2 for suppression of colon cancer
proliferation and transformation. These studies also suggest that
American ginseng might have potential value in colorectal cancer
chemoprevention, and provide a better understanding of the
mechanisms for the beneﬁcial effects of American ginseng in hu-
man health.
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